Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.